Last week saw the newest third-quarter earnings release from Neuronetics, Inc. (NASDAQ:STIM), an important milestone in the company's journey to build a stronger business. Neuronetics reported ...

MALVERN, Pa., March 02, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve ...

Neuronetics, Inc., a medical technology company focused on mental health, has announced key updates regarding its NeuroStar therapy. The company will be a Silver Sponsor at the 13th Annual Clinical ...

This article first appeared on GuruFocus. Neuronetics Inc (NASDAQ:STIM) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $38.06 million, and the ...

"Guidance... remains unchanged" with "total revenue between $160 million and $166 million," "gross margins... between 47% and 49%," "operating expenses in the range ...

Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% ...

PHILADELPHIA, Oct. 16, 2012 /PRNewswire/ -- Neuronetics, Inc., a privately-held medical device company committed to the development of innovative, non-invasive therapies to treat psychiatric ...

Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth ...

Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basis Full year 2025 revenue of $149 ...

MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company ...